On July 8, 2026 Cellis reported to have participated in the International Conference on Precision Medicine and the STRIKE Scientific Meeting, held on 2–4 July 2026 in Messina, Italy. The event brought together leading researchers, clinicians, and industry representatives to discuss the latest advances in precision medicine and translational research.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As an invited speaker, our Chief Scientific Officer, Prof. Magdalena Król, presented the lecture titled "Turning Macrophages into Therapeutic Effectors: Immune Reprogramming via the Macrophage Drug Conjugate Platform."
During her presentation, Prof. Król introduced Cellis’ innovative Macrophage Drug Conjugate (MDC) platform, which harnesses macrophages as active therapeutic effectors capable of delivering anti-cancer payloads directly to the tumor microenvironment. The lecture highlighted how immune cell reprogramming can overcome key limitations of conventional drug delivery and open new opportunities for precision oncology.
The conference provided an excellent opportunity to exchange ideas with scientists, clinicians, and innovators working across cancer biology, immunotherapy, nanomedicine, and targeted drug delivery. The discussions reinforced the growing interest in next-generation cell-based therapies and the importance of interdisciplinary collaboration in accelerating their clinical translation.
We thank the organizers for the invitation and the opportunity to present Cellis’ scientific achievements on an international stage. We look forward to building new collaborations and continuing to advance macrophage-based precision therapies for patients with cancer.
(Press release, Cellis, JUL 8, 2026, View Source [SID1234669103])